858
Views
21
CrossRef citations to date
0
Altmetric
Drug Profile

Entrectinib for the treatment of metastatic NSCLC: safety and efficacy

ORCID Icon, ORCID Icon, , , & ORCID Icon
Pages 333-341 | Received 13 Dec 2019, Accepted 19 Mar 2020, Published online: 08 Apr 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yuanyuan Jiang, Lanxin Liu, Morenci Manning, Madison Bonahoom, Aaron Lotvola, Zhe Yang & Zeng-Quan Yang. (2022) Structural analysis, virtual screening and molecular simulation to identify potential inhibitors targeting 2'-O-ribose methyltransferase of SARS-CoV-2 coronavirus. Journal of Biomolecular Structure and Dynamics 40:3, pages 1331-1346.
Read now

Articles from other publishers (20)

Essam A. Ali, Muzaffar Iqbal, Gamal A. E. Mostafa & Rashad Al Salahi. (2023) Development and Validation of an Ecofriendly, Rapid, Simple and Sensitive UPLC-MS/MS Method for Entrectinib Quantification in Plasma for Therapeutic Drug Monitoring. Separations 10:9, pages 494.
Crossref
Adarsh Kumar, Ankit Kumar Singh, Harshwardhan Singh, Veena Vijayan, Deepak Kumar, Jashwanth Naik, Suresh Thareja, Jagat Pal Yadav, Prateek Pathak, Maria Grishina, Amita Verma, Habibullah Khalilullah, Mariusz Jaremko, Abdul-Hamid Emwas & Pradeep Kumar. (2023) Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective. Pharmaceuticals 16:2, pages 299.
Crossref
Tomer Meirson, Valerio Nardone, Francesca Pentimalli, Gal Markel, David Bomze, Maria D’Apolito, Pierpaolo Correale, Antonio Giordano, Luigi Pirtoli, Camillo Porta, Steven G Gray & Luciano Mutti. (2022) Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology. Journal of Translational Medicine 20:1.
Crossref
Yang Miao, Xiaohe Li, Yue Yang, Jianwei Zhang, Li Chen, Qianyi Zhang, Wenqi Li, Ying Liu, Xianfeng Zhang, Ruimin Gu & Cheng Yang. (2022) Entrectinib ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β1 signaling pathway. International Immunopharmacology 113, pages 109427.
Crossref
Christine Martineau, Maria-Kim Turcotte, Noémie Otis, Frédéric Provost, Ludovic Themens, Marie-Pascale Guay, Nathalie Letarte & Jean-Philippe Adam. (2022) Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review. Supportive Care in Cancer 30:12, pages 10471-10482.
Crossref
Suvadeep Mal, Udita Malik, Monalisa Mahapatra, Abhishek Mishra, Dilipkumar Pal & Sudhir K. Paidesetty. (2022) A review on synthetic strategy, molecular pharmacology of indazole derivatives, and their future perspective. Drug Development Research 83:7, pages 1469-1504.
Crossref
Matthias Schürmann, Peter Goon & Holger Sudhoff. (2022) Review of potential medical treatments for middle ear cholesteatoma. Cell Communication and Signaling 20:1.
Crossref
Diego Kauffmann-Guerrero & Amanda Tufman. (2022) Rare driver alterations in nonsmall cell lung cancer: novel targeted drugs. Current Opinion in Oncology 34:1, pages 77-82.
Crossref
Michael Burger & Joachim P. Steinbach. 2022. Therapie-Handbuch - Onkologie und Hämatologie. Therapie-Handbuch - Onkologie und Hämatologie 461 467 .
Rohit Bhatia & Rajesh K. Singh. 2021. Protein Kinases - Promising Targets for Anticancer Drug Research. Protein Kinases - Promising Targets for Anticancer Drug Research.
Lei Zhang, Huanhuan Liu, Ye Tian, Huina Wang & Xueying Yang. (2021) A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report. BMC Pulmonary Medicine 21:1.
Crossref
Jong-Won Kim. (2021) Diagnostic Classification and Genomic Analyses of Cancer. Laboratory Medicine Online 11:4, pages 223-229.
Crossref
Xiaoxia Liang, Pan Wu, Qian Yang, Yunyu Xie, Changliang He, Lizi Yin, Zhongqiong Yin, Guizhou Yue, Yuanfeng Zou, Lixia Li, Xu Song, Cheng Lv, Wei Zhang & Bo Jing. (2021) An update of new small-molecule anticancer drugs approved from 2015 to 2020. European Journal of Medicinal Chemistry 220, pages 113473.
Crossref
Xiaoxia Liang, Qian Yang, Pan Wu, Changliang He, Lizi Yin, Funeng Xu, Zhongqiong Yin, Guizhou Yue, Yuanfeng Zou, Lixia Li, Xu Song, Cheng Lv, Wei Zhang & Bo Jing. (2021) The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020. Bioorganic Chemistry 113, pages 105011.
Crossref
Kazuhiro Sase, Yasuhito Fujisaka, Masaaki Shoji & Mikio Mukai. (2021) Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments. Current Treatment Options in Oncology 22:8.
Crossref
Paul Hofman. (2021) What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy. Journal of Molecular Pathology 2:2, pages 147-172.
Crossref
Sara Elena Rebuzzi, Lodovica Zullo, Giovanni Rossi, Massimiliano Grassi, Veronica Murianni, Marco Tagliamento, Arsela Prelaj, Simona Coco, Luca Longo, Maria Giovanna Dal Bello, Angela Alama, Chiara Dellepiane, Elisa Bennicelli, Umberto Malapelle & Carlo Genova. (2021) Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences 22:5, pages 2625.
Crossref
Taranom Mobasheri, Elham Rayzan, Mahsima Shabani, Mina Hosseini, Ghanbar Mahmoodi Chalbatani & Nima Rezaei. (2020) Neuroblastoma‐targeted nanoparticles and novel nanotechnology‐based treatment methods. Journal of Cellular Physiology 236:3, pages 1751-1775.
Crossref
Yalin Kang, Yu Jin, Qianxia Li & Xianglin Yuan. (2021) Advances in Lung Cancer Driver Genes Associated With Brain Metastasis. Frontiers in Oncology 10.
Crossref
Juliana F. Vilachã, Sarah C. Mitchel, Muluembet Z. Akele, Stephen Evans & Matthew R. Groves. (2020) Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. Crystals 10:9, pages 725.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.